Knorr Health Strategy and Diapharm announce cooperation

02.04.2015 12:17

The market access consultancy Knorr Health Strategy and the pharmaceutical service provider Diapharm are cooperating in the further development of the research series “Market Access Compass” and “AMNOG Monitor”. Both formats are now offered in combination at special conditions. It is still possible to purchase the “Market Access Compass” and the “AMNOG Monitor” individually.

The collaboration complements each other excellently, emphasizes Carolin Knorr, Managing Director of Knorr Health Strategy: “Diapharm and Knorr Health Strategy both embody the same values: AMNOG competence, science and exclusivity. Our customers can now use our 'Market Access Compass' and Diapharm's 'AMNOG Monitor' at the same time. The two working aids form a unique, comprehensive and continuously updated source of information for benefit assessment in accordance with Section 35a SGB V and price negotiations in accordance with Section 130b SGB V. In addition, we are also planning to expand joint activities in the creation of benefit dossiers.

“Together, 'AMNOG Monitor' and 'Market Access Compass' offer unparalleled precise analyzes of the benefit assessment process, including concrete recommendations,” explains Ralf Sibbing, Managing Director of Diapharm: “The evaluations include the G-BA's decision-making practice, strategic aspects of the
Reimbursement price negotiations and the development of manufacturer selling prices.”